Browse by:

Ed Fenton named to NHMA post

Gregory Seay |

Connecticut's leading manufacturers' lobby has named M. Edward Fenton as its new executive director, effective July 1.

Alexion paying up to $80M to develop new drug

Patricia Daddona |

Rare disease drugmaker Alexion Pharmaceuticals Inc. is paying up to $80 million plus royalties to license a Canadian firm's drug delivery technology to develop an undisclosed drug.

Trump's double down on defense would buy more Black Hawks, F-35s


On the same day President Trump rolled out his fiscal 2018 budget, which boosted defense spending, he also asked Congress for $30 billion in extra funding for the Pentagon, in part so it could...

UTC's Carrier settles patent infringement lawsuit

Patricia Daddona |

Carrier, a division of Farmington-based United Technologies Corp., has settled a patent infringement lawsuit against Houston, Tex.-based Goodman Manufacturing Co. L.P.

New Britain's Stanley completes $1.95B Newell buy

Patricia Daddona |

New Britain toolmaker Stanley Black & Decker Inc. has completed its $1.95 billion cash purchase of Newell Brands Inc.

Report: Alexion to cut 7% of workforce

Patricia Daddona |

New Haven-based Alexion Pharmaceuticals Inc. is restructuring its workforce, which will impact about 7 percent of its employee base.

South Windsor firm wins European bone implant patent

Patricia Daddona |

South Windsor's Oxford Performance Materials Inc. said Monday it has been granted a European patent for its biomedical division's customized bone replacement implant.

FuelCell’s 1Q red ink grows

Matt Pilon |

A steep drop in product sales revenue helped drive a larger first-quarter loss for Danbury’s FuelCell Energy, the manufacturer reported Thursday.

Stanley closes $900M Craftsman deal

Gregory Seay |

New Britain's Stanley Black & Decker has finalized its approximately $900 million cash purchase of the Craftsman tool brand from Sears Holdings.

FDA to review Alexion drug as treatment for neuromuscular disease

Patricia Daddona |

Alexion Pharmaceuticals Inc.'s drug Soliris will be reviewed by the U.S. Food and Drug Administration as a potential treatment for a debilitating neuromuscular disease (myasthenia gravis), the...

Copyright 2017 New England Business Media